Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
32.2M
-
Shares change
-
-2.6M
-
Total reported value, excl. options
-
$225M
-
Value change
-
-$28.7M
-
Put/Call ratio
-
0.48
-
Number of buys
-
61
-
Number of sells
-
-49
-
Price
-
$7.01
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q3 2021
132 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q3 2021.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.2M shares
of 49.6M outstanding shares and own 64.8% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (3.63M shares), Camber Capital Management LP (3.43M shares), BlackRock Inc. (3.21M shares), FRED ALGER MANAGEMENT, LLC (2.47M shares), MILLENNIUM MANAGEMENT LLC (1.67M shares), RENAISSANCE TECHNOLOGIES LLC (1.63M shares), Palo Alto Investors LP (1.39M shares), GREAT POINT PARTNERS LLC (1.3M shares), ACADIAN ASSET MANAGEMENT LLC (1.3M shares), and AIGH Capital Management LLC (864K shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.